| Sep 26 |
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
|
| Aug 8 |
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Century Therapeutics GAAP EPS of -$0.38, revenue of $0.8M
|
| Aug 8 |
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Jul 12 |
After losing 17% in the past year, Century Therapeutics, Inc. (NASDAQ:IPSC) institutional owners must be relieved by the recent gain
|
| Jul 9 |
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
|
| Jun 20 |
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
|
| Jun 18 |
Century Therapeutics files to sell 7.87M shares of common stock for holders
|
| Jun 3 |
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
|
